Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
Spectrum Pharmaceuticals, Inc. (NQ: SPPI)
8.140 USD  +0.060 (+0.74%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Spectrum Pharmaceuticals, Inc.
 
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Spectrum Pharmaceuticals (SPPI) Said FDA Accepted FUSILEV sNDA For Colorectal Cancer
March 26, 2009
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4514168 for the full story. Read More
from StreetInsider.com News Articles
Spectrum Pharmaceuticals Announces That FDA Has Accepted FUSILEV™ sNDA for Colorectal Cancer Indication
March 26, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN®, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin’s Lymphoma
March 16, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy
February 25, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals Strengthens Management, Realigns Resources to Focus on Commercialization and Near-Term Opportunities
February 25, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC™ Joint Venture upon CTI's Fulfillment of Closing Conditions
February 23, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
February 04, 2009
from Business Wire News Releases
ZEVALIN® Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study
January 22, 2009
from Business Wire News Releases
Spectrum Pharmaceuticals and Cell Therapeutics Close Transaction to Market ZEVALIN® by Forming RIT Oncology LLC, a Joint Venture
December 16, 2008
from Business Wire News Releases
Levoleucovorin (FUSILEV™) Listed in the NCCN Drugs & Biologics Compendium™ and NCCN Updates Clinical Practice Guidelines in Oncology™
December 11, 2008
from Business Wire News Releases
ZEVALIN Consolidation in First-Line Therapy in Patients with Non-Hodgkin’s Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months
December 08, 2008
from Business Wire News Releases
ZEVALIN® Data to Be Presented at 2008 Annual Meeting of the American Society of Hematology
December 04, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009
December 01, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy
December 01, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
November 26, 2008
from PR Newswire
Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review
November 07, 2008
-- Approximately $90 Million in Cash and Equivalents as of November 6, 2008 -- Signed Collaboration Agreement With Allergan, Inc. for Apaziquone (EOquin(R)) on October 28, 2008 -- FUSILEV(TM)... Read More
from Business Wire News Releases
FUSILEV(TM) Receives Unique, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)
November 07, 2008
-- FUSILEV(TM), the Company's First Proprietary Oncology Drug, Approved Earlier This Year -- FUSILEV(TM) Launched August 15th -- Supplemental New Drug Application for Advanced Metastatic Colorectal... Read More
from Business Wire News Releases
Spectrum Pharmaceuticals Announces Receipt of $41.5 Million from Allergan, Inc. Per Collaboration Agreement for Apaziquone Announced on October 29th
November 06, 2008
-- Spectrum Will Receive Up To An Additional $304 Million Based On Achievement Of Certain Clinical, Regulatory And Commercialization Milestones -- Spectrum Will Continue to Conduct Clinical Trials --... Read More
from Business Wire News Releases
Spectrum Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Investment Conference
November 05, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals Announces Third Quarter 2008 Corporate Update and Pipeline Review Conference Call
November 04, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
November 03, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
October 31, 2008
from Business Wire News Releases
Allergan (AGN) and Spectrum Pharmaceuticals (SPPI) Announce Collaboration Agreement for Apaziquone (EOquin(R))
October 29, 2008
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4104792 for the full story. Read More
from StreetInsider.com News Articles
Allergan, Inc. and Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone (EOquin(R))
October 29, 2008
-- Apaziquone is Currently Being Investigated for the Treatment of Non-Muscle Invasive Bladder Cancer -- Spectrum to Receive $41.5 Million at Closing and up to $304 Million in Milestone Payments --... Read More
from Business Wire News Releases
Spectrum Pharmaceuticals to Present at Seventh Annual BIO Investor Forum
October 28, 2008
from Business Wire News Releases
BIOCOM Announces Final Schedule for BIOCOM Investor Conference
October 24, 2008
from PR Newswire
Spectrum Pharmaceuticals to Present at BIOCOM's Third Annual Investor Conference
October 24, 2008
from Business Wire News Releases
Spectrum Pharmaceuticals to Present at the JMP Securities Focus on Healthcare Conference
September 30, 2008
from Business Wire News Releases
Pharma Partnership in the 4th Quarter 2008 (SPPI, rated BUY)
September 18, 2008
They should annnounce a pharma partnership in the 4th quarter 2008 which will provide more funding for development of their various drugs which are in product development.  They are presently trading... Read More
category Healthcare , Biotechnology & Drugs
from SocialPicks.com: Front Page Picks
Spectrum Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2008
September 12, 2008
-- Recently Launched FDA Approved Drug - FUSILEV(TM) -- EOquin(R) In Phase 3 Registrational Trials in Non-Muscle Invasive Bladder Cancer Read More
from Business Wire News Releases
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here